Search-led Peptide Reference
Ipamorelin ghrelin-receptor selectivity: evidence and COA guide
Source-based guide to Ipamorelin mechanism ghrelin receptor selectivity COA purity, with molecular identity, evidence limits, analytical checks and dated regulatory verification.
Direct answer
Popular summaries overstate “selectivity” unless the underlying receptor panel, species and assay conditions are identified.
Search engines and AI summaries often collapse aliases, molecule classes, preclinical observations and regulatory events into one confident sentence. A reliable archive record keeps those fields separate and links each claim to a date-stamped primary source.
Name and molecular identity
Ipamorelin is indexed as a growth-hormone secretagogue and ghrelin-receptor agonist in experimental literature.
Use LC-MS for identity, a resolving HPLC method for related substances, and explicit counterion, water and net-content reporting.
| Identity field | What to verify |
|---|---|
| Name and aliases | Exact spelling, development code and whether an alias is molecule-specific |
| Structure | Sequence or chemical structure, termini, modification and conjugation |
| Molecular form | Free form, salt/counterion, hydration state and calculated mass basis |
| Analytical support | Orthogonal identity, purity, content and lot-linked raw-data references |
How to compare without overclaiming
Contrast Ipamorelin with GHRP-2, GHRP-6 and GHRH analogues by receptor class first; combined-product marketing is not combination-efficacy evidence.
Cross-study comparisons require matched populations, models, exposure, duration, endpoints and analysis methods. A receptor label, publication count or high HPLC area percentage cannot by itself establish clinical equivalence, safety, effectiveness or sample identity.
Evidence and status review
Extract receptor assay format, concentration range, comparator ligands and off-target panel. Separate pharmacology studies from clinical outcome claims and from unverified wellness content.
- Start with the exact name and development code in PubMed and a trial registry.
- Separate biochemical, cellular, animal and human evidence.
- Record the jurisdiction and document date for every regulatory claim.
- Open the primary paper or regulator document instead of citing a search snippet.
- Mark missing sequence, method or lot information as unknown rather than inferred.
COA and procurement-document checklist
- Product name, sequence or structure and declared molecular form agree across label, specification and COA.
- Batch number, test date, method identifier and approval/version fields are present.
- Identity, chromatographic purity and net content are reported as different measurements.
- Chromatogram and mass data correspond to the same lot and are reviewable.
- Water, counterion, residual solvent, elemental or endotoxin tests are included when scientifically relevant.
Primary-source verification routes
Statuses and database records change. Save the document date, jurisdiction, registry identifier and access date; use the primary document for consequential claims.